Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

XL-888

Generic Name: XL-888

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₇N_₅O_₃

CAS Number: 1149705-71-4

Unique Ingredient Identifier: 7M346920EV

Overview

XL888 has been used in trials studying the treatment of Cancer and Melanoma.

Background

XL888 has been used in trials studying the treatment of Cancer and Melanoma.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

Phase 1

Completed

Posted: 2017/03/30

Sponsor:Emory University

ID:NCT03095781

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1

Active, not recruiting

Posted: 2016/03/29

Sponsor:H. Lee Moffitt Cance...

ID:NCT02721459

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1

Completed

Posted: 2012/08/06

Sponsor:H. Lee Moffitt Cance...

ID:NCT01657591

Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors

Phase 1

Terminated

Posted: 2008/11/24

Sponsor:Exelixis

ID:NCT00796484

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy